In-depth guide

UPDATED FEB 2026

Depo-Provera Alternatives After Diagnosis

Part of the Depo-Provera Brain Tumor investigation

The short answer

If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

Discontinuing Depo-Provera After Diagnosis

The updated FDA label (December 2025) instructs healthcare providers to "discontinue Depo-Provera CI if a meningioma is diagnosed." Stopping MPA exposure removes the hormonal stimulus that drives meningioma growth through progesterone receptor activation. Some patients have experienced tumor stabilization or even shrinkage after discontinuing progestin medications.

Safer Contraceptive Options

Copper IUD (Paragard) — hormone-free, highly effective, 10-year duration. Barrier methods (condoms, diaphragm) — no hormonal exposure. Tubal ligation / vasectomy — permanent options. Non-progestin hormonal options should be discussed carefully with your doctor given the progesterone receptor mechanism.

What About Other Progestins?

The EMA review noted that the meningioma risk is primarily associated with high-dose and depot (injected) MPA. Low-dose progestin contraceptives (hormonal IUDs like Mirena, progestin-only pills) have not shown the same magnitude of risk. However, given the progesterone receptor mechanism, women diagnosed with meningioma should discuss all hormonal contraception with their doctor.

Ongoing Monitoring

After a meningioma diagnosis, regular MRI monitoring is standard of care — typically every 6–12 months initially, then annually. If you discontinue Depo-Provera and the tumor remains stable, your neurologist may extend monitoring intervals. Document all monitoring visits and results for your legal case.

Research & evidence

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health

View on PubMed

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ

View on PubMed

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Griffin BR et al. (2024). Cancers

View on PubMed

FAQ

Frequently Asked Questions

37 QUESTIONS

Studies show that long-term use of Depo-Provera significantly increases the risk of meningioma — a tumor in the tissue surrounding the brain. The risk ranges from 1.5x to 5.6x depending on duration of use and the study population. Meningiomas express progesterone receptors at 60–80% rates, and the synthetic progestin in Depo-Provera (MPA) stimulates tumor growth by binding to these receptors.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Depo-Provera Brain Tumor Investigation